Powder: -20°C for 3 years | In solvent: -80°C for 1 year
E1231 是 SIRT1 的激活剂。 E1231 通过增强 ABCA1 表达来防止实验性动脉粥样硬化并降低血浆胆固醇和甘油三酯。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 471 | 现货 | ||
5 mg | ¥ 1,160 | 现货 | ||
10 mg | ¥ 1,830 | 现货 | ||
25 mg | ¥ 3,660 | 现货 | ||
50 mg | ¥ 5,360 | 现货 | ||
100 mg | ¥ 7,530 | 现货 | ||
500 mg | ¥ 14,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,280 | 现货 |
产品描述 | E1231 is an activator of SIRT1 . E1231 protects from experimental atherosclerosis and lowers plasma cholesterol and triglycerides by enhancing ABCA1 expression. |
体外活性 | E1231, a piperazine 1,4-diamide compound, was identified as a SIRT1 activator with EC50value of 0.83 μM. E1231 interacted with recombinant human SIRT1 protein and deacetylated liver X receptor-alpha (LXRα). E1231 increased ATP-binding cassette transporter A1 (ABCA1) expression in RAW 264.7 cells dependent on SIRT1 and LXRα. E1231 promoted cholesterol efflux and inhibited lipid accumulation in RAW 264.7 cells via SIRT1 and ABCA1. In the golden hamster hyperlipidemia model, E1231 treatment decreased total cholesterol and triglyceride levels in both serum and the liver, while increased cholesterol content in feces. Moreover, E1231 increased ABCA1 and SIRT1 protein expression in the liver. In ApoE-/-?mice, E1231 treatment reduced atherosclerotic plaque development compared with untreated ApoE-/-?mice. |
细胞实验 | A high-throughput screening assay was established to identify SIRT1 activators. Surface plasmon resonance and immunoprecipitation were performed to confirm the interaction of E1231 with SIRT1. Cholesterol assay was performed to demonstrate the in vitro effect of E1231. The in vivo effect of E1231 was evaluated in experimental models |
分子量 | 363.41 |
分子式 | C21H21N3O3 |
CAS No. | 1031195-19-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/ml (165.1 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.7517 mL | 13.7586 mL | 27.5171 mL | 68.7928 mL |
5 mM | 0.5503 mL | 2.7517 mL | 5.5034 mL | 13.7586 mL | |
10 mM | 0.2752 mL | 1.3759 mL | 2.7517 mL | 6.8793 mL | |
20 mM | 0.1376 mL | 0.6879 mL | 1.3759 mL | 3.4396 mL | |
50 mM | 0.055 mL | 0.2752 mL | 0.5503 mL | 1.3759 mL | |
100 mM | 0.0275 mL | 0.1376 mL | 0.2752 mL | 0.6879 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
E1231 1031195-19-3 Chromatin/Epigenetic DNA Damage/DNA Repair Sirtuin E-1231 E 1231 Inhibitor inhibitor inhibit